.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Moodys
Fish and Richardson
AstraZeneca
US Army
Teva
Daiichi Sankyo
Citi
Baxter
Johnson and Johnson

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020951

« Back to Dashboard
NDA 020951 describes TAGAMET HB 200, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the TAGAMET HB 200 profile page.

The generic ingredient in TAGAMET HB 200 is cimetidine. There are twenty-five drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the cimetidine profile page.

Summary for NDA: 020951

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SUSPENSION;ORALStrength200MG/20ML
Approval Date:Jul 9, 1999TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
US Army
Mallinckrodt
McKesson
Julphar
Moodys
Merck
Queensland Health
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot